CA3040173A1 - Pyrimido-diazepinone kinase scaffold compounds and methods of treating dclk1/2-mediated disorders - Google Patents

Pyrimido-diazepinone kinase scaffold compounds and methods of treating dclk1/2-mediated disorders Download PDF

Info

Publication number
CA3040173A1
CA3040173A1 CA3040173A CA3040173A CA3040173A1 CA 3040173 A1 CA3040173 A1 CA 3040173A1 CA 3040173 A CA3040173 A CA 3040173A CA 3040173 A CA3040173 A CA 3040173A CA 3040173 A1 CA3040173 A1 CA 3040173A1
Authority
CA
Canada
Prior art keywords
alkyl
optionally substituted
compound
aryl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3040173A
Other languages
English (en)
French (fr)
Inventor
Fleur M. FERGUSON
Nathanael S. Gray
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of CA3040173A1 publication Critical patent/CA3040173A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3040173A 2016-10-18 2017-10-18 Pyrimido-diazepinone kinase scaffold compounds and methods of treating dclk1/2-mediated disorders Pending CA3040173A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662409457P 2016-10-18 2016-10-18
US62/409,457 2016-10-18
PCT/US2017/057126 WO2018075608A1 (en) 2016-10-18 2017-10-18 Pyrimido-diazepinone kinase scaffold compounds and methods of treating dclk1/2-mediated disorders

Publications (1)

Publication Number Publication Date
CA3040173A1 true CA3040173A1 (en) 2018-04-26

Family

ID=62018969

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3040173A Pending CA3040173A1 (en) 2016-10-18 2017-10-18 Pyrimido-diazepinone kinase scaffold compounds and methods of treating dclk1/2-mediated disorders

Country Status (6)

Country Link
US (1) US11028089B2 (enExample)
EP (1) EP3528814B1 (enExample)
JP (1) JP7086948B2 (enExample)
AU (1) AU2017346845B2 (enExample)
CA (1) CA3040173A1 (enExample)
WO (1) WO2018075608A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017177092A1 (en) * 2016-04-07 2017-10-12 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods of treating pi3k-mediated disorders
WO2019126696A1 (en) 2017-12-22 2019-06-27 Dana-Farber Cancer Institute, Inc. Nek inhibitors and methods of use
WO2020206608A1 (en) 2019-04-09 2020-10-15 Ranok Therapeutics (Hangzhou) Co., Ltd. Methods and compositions for targeted protein degradation
US20220280530A1 (en) * 2019-08-08 2022-09-08 Anhui Newstar Pharmaceutical Development Co., Ltd. Prevention or treatment of diseases and disorders associated with tissue damage
AU2021218739A1 (en) * 2020-02-14 2022-09-22 Salk Institute For Biological Studies Inhibitors of ULK1/2 and methods of using same
EP4229061A4 (en) * 2020-10-14 2024-09-25 Ranok Therapeutics (Hangzhou) Co. Ltd. METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION
CN116940577A (zh) * 2021-03-09 2023-10-24 詹森药业有限公司 作为细胞周期蛋白依赖性激酶7（cdk7）抑制剂的三环吡啶
CN115707469B (zh) * 2021-08-19 2024-07-02 首都医科大学附属北京朝阳医院 Dclk1抑制剂和tki在制备肺腺癌药物中的应用
CN114478539B (zh) * 2022-02-09 2024-02-02 中国人民解放军海军军医大学 一种新型dclk1抑制剂及其制备方法和应用
CN115969978A (zh) * 2022-10-27 2023-04-18 首都医科大学附属北京朝阳医院 Dclk1及il6/stat3通路抑制剂在治疗三阴性乳腺癌中的应用
CN115814094B (zh) * 2023-01-04 2024-04-02 暨南大学附属第一医院（广州华侨医院） Dclk抑制剂在制备治疗脊髓损伤的药物中的应用
CN116375713B (zh) * 2023-03-07 2024-11-19 中国人民解放军海军军医大学 一种dclk1蛋白降解靶向嵌合体及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2379559B1 (en) * 2009-01-06 2017-10-25 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
ES2693152T3 (es) * 2011-05-10 2018-12-07 Kyowa Hakko Kirin Co., Ltd. Compuesto de pirimido-diazepinona
WO2014160430A1 (en) * 2013-03-13 2014-10-02 Georgetown University Small molecule lrrk2 and erk5 inhibitors
EP3670515B1 (en) 2013-03-15 2024-03-06 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone compounds and methods of treating disorders
WO2015117087A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
KR20160111036A (ko) 2014-01-31 2016-09-23 다나-파버 캔서 인스티튜트 인크. 디아제판 유도체 및 그의 용도
EP3177626A4 (en) * 2014-08-08 2017-12-27 Dana Farber Cancer Institute, Inc. Diazepane derivatives and uses thereof
US9694084B2 (en) * 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
WO2016105518A1 (en) * 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
WO2017148406A1 (zh) * 2016-03-04 2017-09-08 安徽省新星药物开发有限责任公司 嘧啶类七元环化合物、其制备方法、药用组合物及其应用

Also Published As

Publication number Publication date
AU2017346845A1 (en) 2019-04-04
JP2019530724A (ja) 2019-10-24
US20190315753A1 (en) 2019-10-17
WO2018075608A1 (en) 2018-04-26
EP3528814B1 (en) 2024-08-14
US11028089B2 (en) 2021-06-08
JP7086948B2 (ja) 2022-06-20
AU2017346845B2 (en) 2021-12-02
EP3528814A4 (en) 2020-07-29
EP3528814A1 (en) 2019-08-28

Similar Documents

Publication Publication Date Title
AU2017346845B2 (en) Pyrimido-diazepinone kinase scaffold compounds and methods of treating DCLK1/2-mediated disorders
CA2902599C (en) Pyrimido-diazepinone compounds and methods of treating disorders
EP3255047B1 (en) Pyrimido-diazepinone kinase scaffold compounds and uses in treating disorders
AU2017248186B2 (en) Pyrimido-diazepinone kinase scaffold compounds and methods of treating PI3K-mediated disorders
CA3020172C (en) Pyrimido-diazepinone kinase scaffold compounds and methods of treating pi3k-mediated disorders
HK1259894A1 (en) Pyrimido-diazepinone compounds and methods of treating disorders
HK1247928B (en) Pyrimido-diazepinone kinase scaffold compounds and uses in treating disorders
HK1247928A1 (en) Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220922

EEER Examination request

Effective date: 20220922

EEER Examination request

Effective date: 20220922

EEER Examination request

Effective date: 20220922

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20240917

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241011

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241011

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241011

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250107

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250212

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250618

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250618